Lentigo maligna treated with 5% imiquimod cream;Lentigo maligno tratado con crema de imiquimod al 5%

Actas Dermo-Sifiliograficas

Volumn 96, Issue 10, 2005, Pages 700-702

  Martín, Trinidad ^a,b   Ojeda, Antonio ^a   Martínez, Silvestre ^a   Vera, Ángel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b NONE   (Spain)

Author keywords

Imiquimod; Lentigo maligna; Lentigo maligna melanoma

Indexed keywords

IMIQUIMOD; IMMUNOMODULATING AGENT;

AGED; ARTICLE; CANCER STAGING; CASE REPORT; CHEMOSURGERY; FEMALE; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; MALIGNANT LENTIGO; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 33644835869     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(05)73162-8     Document Type: Article

References (17)

1. Ackerman AB. The concept of malignant melanoma in situ, in pigment cell. Vol. 8. edited by De Elder. Basel: Karger; 1987. p. 205.
2. Wayte DM, Helwig EB. Melanotic Freckle of Hutchinson. Cancer. 1968;21:893-901.
3. Clark WH, Mihm MC. Lentigo maligna and lentigo maligna melanoma. Am J Pathol. 1969;55:39-67.
4. NIH. Consensos conference. Diagnosis and treatment of early melanoma. JAMA. 1992;268:1314-9.
5. Roberts DLL, Anstey AV, Barlow RJ, et al. Uk guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7-17.
6. Geisse JK, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III randomized, vehicle controlled studies. J Am Acad Dermatol. 2004;50:722-33.
7. Naylor MF, Crowson N, Kuwahara R. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149 Suppl 66:66-9.
8. Kadowaki N, Antonenko S, Ho S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-9.
9. Meyer T, Nindl I, Schmook T, Ultrich C, Sterry W, Stockfleth E. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol. 2003;149:9-13.
10. Powell BAM, Russell-Jones R, Barlow RJ. Topical imiquimod inmunotherapy in the management of lentigo maligna. Clin Dermatol. 2004;29:15-21.
11. Kupfer G, Guillet L. Misery. Topical imiquimod treatment of lentigo maligna: Clinical and histologic evaluation. 2004;51.
12. Ahmed I, Berth-Jones. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-5.
13. Fleming CJ, Bryden AM, Evans A. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485-8.
14. Borucki BU, Metze D. Topical treatment of lentigo maligna with imiquimod 5% cream. Dermatology. 2003;207:326-8.
15. Bong AB, Bonnekoh B, Franke L. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastasis of malignant melanoma. Dermatology. 2002;205:135-8.
16. Fisher GH, Charleston MD, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139:945-7.
17. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.